Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic
Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following
cataract surgery.